Spectrum Pharmaceuticals Inc. (SPPI) announced after the bell Tuesday that Fusilev sales are now expected to be between $10 million and $15 million for the first quarter, and between $80 million and $90 million for the full year 2013.
Spectrum expects full year 2013 revenues of $160 million to $180 million. The consensus estimate is for revenues of $297.33 million.
Spectrum Pharmaceuticals gapped open dramatically lower Wednesday, but was range-bound throughout the session. Shares finished down by 4.64 at $7.79 on the highest volume of the year. The stock sank to a new low for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.